Skin cancer after an organ transplant: why Mohs surgery becomes the default

Every year tens of thousands of people receive a kidney, liver, heart, or lung transplant and begin the medications that keep the new organ alive. Those same medications quietly make the skin the most cancer-prone organ in the body. For transplant recipients, skin cancer is not a remote possibility, it is close to an expectation, and the tumors behave more assertively than they do in other patients. That combination is why Mohs micrographic surgery, the margin-by-margin technique described in what is Mohs surgery, becomes the default treatment for this group rather than a special request.

The risk is not slightly higher, it is an order of magnitude higher. Long-term immunosuppression removes part of the immune surveillance that normally clears sun-damaged cells before they turn into tumors. Solid organ transplant recipients develop cutaneous squamous cell carcinoma at rates commonly reported as roughly 65 to 100 times those of the general population, and the risk keeps climbing with each additional year on the drugs and with the intensity of the regimen (American Academy of Dermatology). The usual ratio also flips. In the general population, basal cell carcinoma is the more common of the two cancers compared in basal cell vs. squamous cell carcinoma. After a transplant, squamous cell carcinoma dominates, often by several times over, and it tends to appear earlier and in greater numbers.

These tumors do not behave like ordinary skin cancers. Squamous cell carcinomas in immunosuppressed patients grow faster, recur more often after treatment, and are more likely to show the microscopic feature called perineural invasion, in which tumor tracks along a small nerve well beyond the visible lesion. They also carry a higher risk of spreading to lymph nodes than the same diagnosis would in an immunocompetent patient (National Cancer Institute). Just as important, they rarely arrive alone. Transplant patients often present with what dermatologists call field cancerization: a whole region of sun-damaged skin, typically the scalp, forehead, backs of the hands, and forearms, studded with actinic keratoses and several carcinomas at once. Learning to read the words on the pathology slip, as covered in what your skin biopsy report means, matters more here because subtype and perineural findings genuinely change the plan.

Why margin control earns its keep in this group. A standard excision estimates the margin and confirms it days later in an outside laboratory. When a tumor is aggressive, poorly defined, and sitting in a field of abnormal skin, that estimate fails more often, and a positive margin means a second operation on tissue that has already been cut. Mohs checks essentially the entire margin under the microscope before the wound is closed, so hidden extensions are found the same day. The appropriate-use logic laid out in when Mohs is the right choice, and when it is not treats immunosuppression itself as a risk factor that pushes a tumor toward Mohs, even in body sites where a low-risk cancer would ordinarily be handled with a simple excision. In practice this means a transplant recipient with a squamous cell carcinoma on the forearm may be offered Mohs where another patient with an identical-looking lesion would not.

What actually changes on the day of surgery. Less than patients expect. The procedure is still done under local anesthesia in an office setting, the rhythm of stages and waiting is unchanged, and immunosuppressant medications are almost always continued without interruption, because the risk of rejection far outweighs any surgical convenience. What changes is the aftercare. Immunosuppression slows wound healing and raises the risk of infection, so surgeons often favor closures with reliable blood supply, keep dressings on longer, leave sutures in a few extra days, and sometimes prescribe preventive antibiotics. Patients on prednisone in particular should expect a slower, less dramatic healing curve. The warning signs reviewed in signs of infection after Mohs surgery deserve a lower threshold to call here, and a wound that stalls rather than steadily improves is worth a same-day phone call rather than a wait for the follow-up visit.

The conversation your transplant team needs to be part of. The single most powerful lever is not surgical. Adjusting the immunosuppressive regimen can measurably lower the rate of new skin cancers, and switching selected patients from a calcineurin inhibitor to an mTOR inhibitor such as sirolimus has been shown in randomized trials to reduce subsequent squamous cell carcinomas, at the cost of side effects that not everyone tolerates. That decision belongs to the transplant physician, not the dermatologist, but it starts with the dermatologist reporting how many cancers a patient is accumulating. Oral acitretin, a low-dose retinoid, is another established option that reduces new keratinocyte cancers in high-risk recipients while it is being taken. Nicotinamide, a form of vitamin B3 available over the counter, reduced new keratinocyte cancers by about 23 percent over twelve months in a randomized trial of people with a history of multiple skin cancers (New England Journal of Medicine, 2015); a later randomized trial specifically in organ transplant recipients did not reproduce that benefit, so it is a reasonable low-risk addition rather than a proven one for this population.

Surveillance is the other half of the treatment. Most transplant dermatology programs recommend a full-skin examination starting within the first year after transplant and repeating every six to twelve months, tightening to every three months for patients who are producing multiple cancers a year. Between visits, the self-check habit and the year-round sun protection described in after a skin cancer: preventing the next one do real work, because a squamous cell carcinoma caught at four millimeters is a very different procedure from the same tumor caught at fifteen. Treating the surrounding precancerous field, with topical agents, cryotherapy, or photodynamic therapy, is often scheduled alongside surgery rather than instead of it.

Questions worth bringing to the consult. Ask whether your surgeon regularly treats transplant recipients and whether the practice coordinates with transplant teams, using the due-diligence approach in finding a qualified Mohs surgeon. Ask whether this particular tumor shows perineural invasion or other high-risk features, whether imaging or a specialist referral is warranted, and how the surgeon will communicate the pathology back to your transplant physician. Ask what surveillance interval they want, and ask, out loud, whether your regimen is worth revisiting with the team that manages it.

The takeaway. After a transplant, skin cancer stops being an occasional nuisance and becomes a chronic condition to be managed for life. The good news is that the management is well understood: aggressive tumors treated with margin-controlled surgery, precancerous fields treated alongside them, a surveillance schedule that runs in months rather than years, and an honest conversation with the transplant team about whether the immunosuppression itself can be adjusted. Patients who set that system up early rarely face the disfiguring, late-stage tumors that make this diagnosis frightening. General patient guidance on skin cancer is maintained by the NIH (MedlinePlus: skin cancer).

Related reading: When Mohs is the right choice, and when it is not.